- Entry
- $0.91
- Final
- $0.8441 -7.2%
- Target
- —
- Score
- -0.72
One of the more interesting things about MYNZ right now is the size of the company compared to the number of catalysts surrounding it. Mainz Biomed currently has a market cap of about $10.5M with roughly 9.1M shares outstanding. That is extremely small for a Nasdaq listed biotech, especially one with multiple clinical programs and partnerships already in place. Yet the company has several developments that investors appear to be paying attention to. First is the pancreatic cancer detection program. …
— ORIGINAL POST ·
MYNZ is a $10.5M biotech with multiple catalysts
· r/investing
· Mar 5, 2026